Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan: A nation-wide community-based study.

Medicine (Baltimore)

Division of Infectious Diseases, Department of Internal Medicine Center for Aging and Health, Changhua Christian Hospital, Changhua City Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.

Published: February 2018

Older adults, particularly those with chronic obstructive pulmonary disease, are advised to receive 23-valent pneumococcal polysaccharide vaccine (PPV23). However, the PPV23 vaccination rate in Taiwan and the determinants of receipt remain unclear.We analyzed the data of 1475 community-dwelling older adults aged ≥75 years who participated in the Healthy Aging Longitudinal Study in Taiwan. Each participant received assessments of PPV23 status, sociodemographic factors (age, sex, education level, marital status, living alone, and occupation), and health-related factors (chronic diseases, smoking status, alcohol intake, physical activities, cognitive status, and physical performance). PPV23 rate was defined as the number of participants who reported receiving free PPV23 divided by the total number of candidates for free PPV23. Multinomial logistic regression analysis was applied to investigate the sociodemographic and health-related determinants of PPV23 status.A PPV23 vaccination rate of 20.7% (305/1475) was observed. Participants who were female, current smokers, and had a low peak expiratory flow were associated with PPV23 nonreceipt (all P <.05). Of the participants who had a low peak expiratory flow, low education status, and physical inactivity were associated with PPV23 nonreceipt (all P <.05).The PPV23 vaccination rate among adults aged ≥75 years was low. Older adults who were women, current smokers, or who had a low PEF were less likely to receive the PPV23. These findings support continual efforts to improve the PPV23 coverage rate in vulnerable populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805441PMC
http://dx.doi.org/10.1097/MD.0000000000009773DOI Listing

Publication Analysis

Top Keywords

ppv23
9
23-valent pneumococcal
8
pneumococcal polysaccharide
8
polysaccharide vaccine
8
older adults
8
ppv23 vaccination
8
vaccination rate
8
free ppv23
8
vaccination coverage
4
coverage associated
4

Similar Publications

Background: Pneumococcal disease, caused by Streptococcus pneumoniae, imposes a significant global health burden, particularly affecting vulnerable groups such as the elderly and immunocompromised. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is designed to protect against 23 serotypes of Streptococcus pneumoniae. However, there is ongoing debate about its effectiveness in reducing all-cause mortality.

View Article and Find Full Text PDF

Pneumococcal disease (PD), caused by , is a serious global health issue, primarily for adults over 65, due to its high mortality and morbidity rates. Recently, broader-serotype vaccines have been introduced to cope with tremendous hospital costs and decreasing quality of life. Our study aims to systematically review the cost-effectiveness of current PCVs (pneumococcal conjugate vaccines) and PPVs (pneumococcal polysaccharide vaccine) from 2018 to April 2024.

View Article and Find Full Text PDF

Background: Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency.

View Article and Find Full Text PDF

Immunization with recombinant PgdA protects mice against lung invasion.

Exp Biol Med (Maywood)

October 2024

Department of Laboratory Medicine, Key Laboratory of Diagnostic Medicine (Ministry of Education), Chongqing Medical University, Chongqing, China.

Current pneumococcal vaccines, including the pneumococcal polysaccharide (PPV23) and conjugate (PCV13) vaccines, offer protection against specific serotypes but pose risks of serotype replacement that can alter the composition of the nasopharyngeal microbiota. To address this challenge, a novel strategy has been proposed to provide effective protection without disrupting the colonization of other bacterial populations. In our study, we found that subcutaneous immunization with recombinant peptidoglycan N-acetylglucosamine deacetylase A (rPgdA) elicited robust humoral and cellular immune responses, significantly reducing the invasion of pneumoniae in the lungs without affecting nasopharyngeal carriage.

View Article and Find Full Text PDF

[Vaccinations in pulmonary diseases - part 2: herpes zoste, RSV, pneumococcal infection and pertussis].

Dtsch Med Wochenschr

November 2024

Fächerverbund für Infektiologie, Pneumologie und Intensivmedizin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.

Article Synopsis
  • RSV is a common respiratory virus that can seriously affect newborns, infants, and older adults; two new vaccines approved in 2023 provide strong protection without the need for annual boosters.
  • The 20-valent pneumococcal vaccine (PCV20) is now recommended for those over 60 and younger individuals with risk factors, replacing the older 23-valent vaccine.
  • Pertussis is often overlooked in adults, with recommendations for a booster alongside tetanus shots, especially for high-risk groups; shingles (Herpes Zoster) poses risks of severe complications, particularly for those with chronic lung diseases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!